Skip to main content
Signal8

Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc.

NYSE:MTNBHealthcare
-2.39%$1.66
AH Close$1.66+0.00%vs close
Mkt Cap$1.63M
Float897K
O/S980K
Inst Own2.2%
SI5.5%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$10.35M
Total Assets$7.21M
Free Cash Flow-$7.01M
Debt & Equity
Debt 22%
Equity 78%
Total Debt$1.35M
Total Equity$4.83M
Shares Outstanding
Short Interest
Split History2 splits · 2 reverse
2-year cumulative
1:15

Nasdaq bars a compliance period at 1:250

  1. 1:15Reverse split
    Sep 28, 202615 shares → 1
  2. 1:50Reverse split
    Sep 3, 202450 shares → 1
Balance Sheet Details
Assets$7.21M
Liabilities$2.38M
Accounts Receivable$0
Accounts Payable$315K
Inventory$0
PP&E (Net)$673K
Goodwill$0
Intangible Assets$2.26M
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Revenue$0$0$1.1M$3.19M$33K$158K$90K$120K$150K$0$194K$0$0$0
YoY Growth---65.6%9560.6%-79.2%76.3%-25.0%-20.0%------
Cost of Revenue$456K$972K$941K$16.68M$14.58M$14.36M$11.23M$6.79M$9.01M$53K$5.29M$5.18M$0$0
Gross Profit-$456K-$972K$155K-$13.49M-$14.55M-$14.2M-$11.14M-$6.67M-$8.86M-$53K-$5.1M-$5.18M$0$0
Gross Margin--14.1%-423.1%-44090.9%-8968.8%-12409.0%-5568.0%-5919.6%--2621.0%---
Research and Development$85K$11.43M$14.49M$16.68M$14.58M$14.36M$11.23M$6.79M$9.01M$3.95M$5.29M$5.18M$1.76M$79K
Selling, General, and Administrative$6.88M$7.76M$9.43M$11.1M$10.19M$10.01M$7.78M$7.98M$7.64M$4.31M$4.81M$5.29M$1.95M$37K
Other-$456K$0$0-$16.68M-$14.58M-$14.36M-$11.23M$57K$22K-$17K$20K-$25K-$688$0
Total Operating Expenses$6.5M$19.19M$23.92M$11.1M$10.19M$10.01M$7.78M$14.77M$16.65M$8.26M$10.11M$10.46M$3.71M$116K
Operating Income (EBIT)-$6.96M-$20.16M-$23.77M-$24.59M-$24.73M-$24.21M-$18.92M-$14.65M-$16.5M-$8.26M-$9.91M-$10.46M-$3.71M-$116K
Operating Margin---2168.4%-771.3%-74954.5%-15288.4%-21067.4%-12230.9%-11024.6%--5096.0%---
Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Interest Income$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Other Income (Expense)-$3.38M-$4.17M$824K$3.59M$1.45M$1.76M$1.55M$57K$659K$658K$776K$244K-$688$0
Income Before Tax (EBT)-$10.35M-$24.33M-$22.94M-$21M-$23.28M-$22.45M-$17.37M-$14.59M-$15.84M-$7.6M-$9.14M-$10.22M-$3.71M-$116K
Income Tax Expense$0-$80K$0$0$0$0$0-$507K-$357K$0$0$0$0$0
Net Income-$10.35M-$24.25M-$22.94M-$21M-$23.28M-$22.45M-$17.37M-$14.08M-$15.49M-$7.6M-$9.14M-$10.22M-$3.71M-$116K
Net Income Margin---2093.2%-658.6%-70554.5%-14177.0%-19343.4%-11760.4%-10345.9%--4697.0%---
Supplementary Data
EPS-30.00-74.70-79.20-45.00-75.60-78.45-80.55-107.70-128.40-98.85-133.05-238.95-87.00-8.70
Diluted EPS-30.00-74.70-79.20-45.00-75.60-78.45-80.55-107.70-128.40-98.85-133.05-238.95-87.00-8.70
Weighted Average OS364,942324,389289,686289,082280,238262,526193,594130,804120,63376,87368,64142,76942,66713,333
EBITDA-$9.89M-$19.19M-$22M-$20.1M-$22.5M-$23.43M-$18.14M-$14.43M-$16.4M-$8.2M-$9.87M-$10.42M-$3.71M$116K
EBITDA Margin---2007.4%-630.5%-68187.9%-14799.2%-20198.0%-12048.6%-10957.4%--5073.7%---
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Assets
Current Assets
Cash and Cash Equivalents$4M$7.28M$4.79M$6.88M$21.03M$12.43M$22.17M$12.45M$7.31M$4.11M$3.23M$2.59M$10.84M$424K
Short-Term Investments$0$0$8.97M$21.93M$28.59M$46.25M$5.61M$0$0$0$0$0$0$0
Cash and Short-Term Investments$4M$7.28M$13.76M$28.81M$49.62M$58.68M$27.77M$12.45M$7.31M$4.11M$3.23M$2.59M$10.84M$424K
Accounts Receivable$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Inventory$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Other Current Assets$76K$741K$50K$5.72M$50K$136K$250K$100K$155K$156K$100K$100K$0$0
Total Current Assets$4.08M$8.03M$15.54M$34.53M$50.99M$61.55M$29.92M$13.09M$7.96M$4.57M$3.56M$2.81M$10.92M$424K
Long-Term Assets
Property, Plant & Equipment Net$673K$2.16M$5.01M$5.73M$5.78M$4.86M$5.63M$2.04M$1.57M$356K$378K$340K$93K$0
Goodwill$0$0$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$0$0$0
Intangible Assets$2.26M$2.26M$3.02M$3.02M$3.02M$3.02M$3.02M$3.02M$3.02M$3.02M$3.02M$0$0$0
Long-Term Investments$200K$200K$0$200K$0$0$0$0$0$0$0$0$0$0
Deferred Tax Assets$0$0$0$34.05M$0$0$0$0$0$0$0$0$0$0
Other Long-Term Assets$0$0$200K$0$200K$200K$336K$461K$536K$541K$115K$216K$316K$0
Total Long-Term Assets$3.13M$4.62M$9.56M$44.33M$10.33M$9.41M$10.32M$6.86M$6.46M$5.25M$4.85M$556K$409K$0
Other Assets$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Total Assets$7.21M$12.64M$25.1M$78.87M$61.33M$70.97M$40.24M$19.94M$14.42M$9.82M$8.41M$3.36M$11.33M$424K
Liabilities
Current Liabilities
Accounts Payable$315K$95K$514K$618K$937K$350K$679K$296K$583K$476K$498K$271K$397K$60K
Short-Term Debt$696K$0$0$569K$0$0$0$200K$170K$118K$0$0$0$0
Current Income Tax Payable$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Current Unearned Revenue$0$0$0$809K$33K$643K$100K-$83K$30K$0$608K$758K$0$0
Other Current Liabilities$452K$4K$271K$585K$899K$329$862K$1.63M$0$11K$9K$0$0$24K
Total Current Liabilities$1.46M$2.67M$2.62M$4.29M$4.35M$3.57M$3.1M$2.84M$2.22M$1.44M$1.13M$1.12M$859K$84K
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0$0$3.75B$0$0$0$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0$0$0-$341K-$108K-$247K-$1.21M$0$0$0$0
Long-Term Deferred Tax Liabilities$257K$257K$341K$34.39M$341K$341K$341K$341K$848K$1.21M$1.21M$0$0$0
Other Long-Term Liabilities$0$0$0$0$0$0-$3.75B$513K$601K$0$0$0$0$0
Total Long-Term Liabilities$915K$2.38M$3.24M$37.94M$4.48M$3.67M$4.09M$962K$1.52M$1.22M$1.21M$15K$0$0
Other Liabilities$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities$2.38M$5.05M$5.86M$42.23M$8.83M$7.24M$7.19M$3.8M$3.74M$2.67M$2.33M$1.13M$859K$84K
Stockholders' Equity
Preferred Stock$0$0$0$0$0$3.8M$3.99M$9.78M$5.72M$6.09M$0$0$0$457K
Common Stock$1K$1K$22K$22K$22K$20K$16K$11K$9K$6K$6K$3K$3K$1K
Retained Earnings-$210.79M-$199.82M-$175.57M-$152.63M-$131.63M-$107.51M-$84.38M-$65.94M-$51.27M-$35.18M-$23.19M-$14.05M-$3.83M-$118K
Comprehensive Income & Other$0$0-$221K-$824K-$145K$228K-$1K-$439K-$0$0-$0-$0$0$0
Other Stockholders' Equity$215.62M$207.41M$194.8M$189.25M$184.11M$171.22M$117.41M$82.08M$61.95M$42.32M$29.25M$16.28M$14.3M$457K
Total Equity$4.83M$7.59M$19.25M$36.64M$52.49M$63.73M$33.05M$16.14M$10.68M$7.15M$6.07M$2.23M$10.47M$340K
Minority Interest$0$0$0$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities and Equity$7.21M$12.64M$25.1M$78.87M$61.33M$70.97M$40.24M$19.94M$14.42M$9.82M$8.41M$3.36M$11.33M$424K
Supplementary Data
Total Debt$1.35M$2.89M$3.56M$4.12M$4.7M$3.75M$4.23M$391K$265K$144K$11K$60K$0$0
Net Debt-$2.65M-$4.39M-$1.23M-$2.76M-$16.33M-$8.68M-$17.94M-$12.06M-$7.04M-$3.96M-$3.22M-$2.53M-$10.84M-$424K
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Operating Activities
Net Income-$10.35M-$24.25M-$22.94M-$21M-$23.28M-$22.45M-$17.37M-$14.08M-$15.49M-$7.6M-$9.14M-$10.22M-$3.71M-$116K
Depreciation & Amortization$456K$972K$941K$898K$781K$775K$781K$218K$101K$53K$44K$42K$1K$116K
Deferred Income Tax$0-$84K$0$0$0$8K$6K-$507K-$357K$0$0-$1.97M-$326K$0
Stock-Based Compensation$1.02M$3.19M$4.95M$5.23M$4.29M$4.56M$2.99M$3.83M$3.6M$1.52M$1.59M$1.97M$326K$0
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$0$0$0$0$0$0$46K$0$0$0
  Inventory$0$0$0$0$0$0$0$0$0$0$0$0$0$0
  Accounts Payable$220K-$419K-$103K-$321K$588K-$329K$384K-$287K$107K-$22K-$74K-$126K$336K$0
  Other Working Capital-$1.73M$288K$1.77M-$4.47M$947K-$179K-$876K$447K$421K-$72K-$250K$370K$62K$0
Total Working Capital Change-$1.51M-$131K$1.67M-$4.79M$1.53M-$509K-$492K$160K$529K-$94K-$324K$244K$398K$0
Other Non-Cash Items$3.37M$4.41M$108K$504K$1.45M$240K$140$57K$157K$2K$9K$1.97M$326K-$57K
Net Cash from Operating-$7.01M-$15.88M-$15.28M-$19.16M-$15.22M-$17.37M-$14.09M-$10.32M-$11.46M-$6.12M-$7.81M-$7.96M-$2.99M-$57K
Investing Activities
Capital Expenditures$0$0-$218K-$892K-$260K-$6K-$406K-$536K-$942K$0-$76K-$289K-$94K$0
Acquisitions$0$0$0$0$0$8.48M$0$0$0$0$71K$0$0$0
Purchases of Investments$0-$8.44M$0-$9.48M-$23.2M-$72.11M-$5.61M$0$0$0$0$0$0$0
Sales of Investments$0$17.64M$13.46M$15.25M$40.23M$31.45M$0$0$0$0$0$0$0$0
Other Investing Activities$335K$0$0$0$0-$8.48M-$5.61M-$535.92M-$942.18M$0-$5.42M-$399.61M$0$0
Net Cash from Investing$335K$9.21M$13.24M$4.88M$16.77M-$40.67M-$6.01M-$536K-$942K$0-$5K-$289K-$94K$0
Financing Activities
Debt Repaid$9K$5K$7K$20K$30K$55K$82K$59K$17K$16K$48K-$24K-
Common Stock Issuance$129K$9.18M$0$99K$5.58M$46.7M$30.1M$9.24M$1.12M$7.16M$10M$0$15.38M$0
Common Stock Repurchases$0$0$0$0$0$0$0$0$0$0$0$0$0-$2K
Dividends Paid$0$0$0$0$0-$682.8M-$2.23B-$587.14M-$608.34M-$4.39B$0$0$0$0
Other Financing Activities-$29K$0$0$0$1.42M$684.2M$2.26B$603.07M$622.84M$4.39B$8.5M$0-$2.38M$480K
Net Cash from Financing$3.39M$9.17M-$7K$79K$6.96M$48.05M$29.85M$15.87M$15.6M$7M$8.46M$0$13.5M$480K
Forex Effect$0$0$0$194$0$0$0$0$0$0$0$0$0$0
Net Change in Cash-$3.29M$2.5M-$2.04M-$14.2M$8.51M-$9.99M$9.75M$5.01M$3.2M$878K$636K-$8.25M$10.42M$422K
Supplementary Data
Operating Cash Flow-$7.01M-$15.88M-$15.28M-$19.16M-$15.22M-$17.37M-$14.09M-$10.32M-$11.46M-$6.12M-$7.81M-$7.96M-$2.99M-$57K
Capital Expenditure$0$0-$218K-$892K-$260K-$6K-$406K-$536K-$942K$0-$76K-$289K-$94K$0
Free Cash Flow-$7.01M-$15.88M-$15.5M-$20.05M-$15.48M-$17.37M-$14.5M-$10.86M-$12.4M-$6.12M-$7.89M-$8.25M-$3.08M-$57K
Cash at Beginning$7.53M$5.04M$7.08M$21.08M$12.77M$22.76M$13.01M$8M$4.11M$3.23M$2.59M$10.84M$424K$2K
Cash at End$4.25M$7.53M$5.04M$6.88M$21.28M$12.77M$22.76M$13.01M$7.31M$4.11M$3.23M$2.59M$10.84M$424K